Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 2
2003 2
2004 1
2005 1
2008 1
2010 2
2012 1
2013 2
2015 1
2020 1
2021 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
The immunological and virological consequences of planned treatment interruptions in children with HIV infection.
Klein N, Sefe D, Mosconi I, Zanchetta M, Castro H, Jacobsen M, Jones H, Bernardi S, Pillay D, Giaquinto C, Walker AS, Gibb DM, De Rossi A; Paediatric European Network for Treatment of AIDS 11 Trial Team. Klein N, et al. PLoS One. 2013 Oct 23;8(10):e76582. doi: 10.1371/journal.pone.0076582. eCollection 2013. PLoS One. 2013. PMID: 24194841 Free PMC article. Clinical Trial.
Long-term clinical, virological and immunological outcomes following planned treatment interruption in HIV-infected children.
Freguja R, Bamford A, Zanchetta M, Del Bianco P, Giaquinto C, Harper L, Dalzini A, Cressey TR, Compagnucci A, Saidi Y, Riault Y, Ford D, Gibb D, Klein N, De Rossi A; Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team. Freguja R, et al. HIV Med. 2021 Mar;22(3):172-184. doi: 10.1111/hiv.12986. Epub 2020 Oct 29. HIV Med. 2021. PMID: 33124144 Free PMC article.
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
Cressey TR, Green H, Khoo S, Treluyer JM, Compagnucci A, Saidi Y, Lallemant M, Gibb DM, Burger DM; Paediatric European Network for Treatment of AIDS II Study Group. Cressey TR, et al. Clin Infect Dis. 2008 May 15;46(10):1601-8. doi: 10.1086/587657. Clin Infect Dis. 2008. PMID: 18419497 Free PMC article. Clinical Trial.
Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children.
Harrison L, Ananworanich J, Hamadache D, Compagnucci A, Penazzato M, Bunupuradah T, Mazza A, Ramos JT, Flynn J, Rampon O, Mellado Pena MJ, Floret D, Marczynska M, Puga A, Forcat S, Riault Y, Lallemant M, Castro H, Gibb DM, Giaquinto C; Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team. Harrison L, et al. AIDS Behav. 2013 Jan;17(1):193-202. doi: 10.1007/s10461-012-0197-y. AIDS Behav. 2013. PMID: 22584916 Free PMC article. Clinical Trial.
Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children.
Paediatric European Network for Treatment of AIDS (PENTA). Paediatric European Network for Treatment of AIDS (PENTA). AIDS. 2015 Nov 28;29(18):2447-57. doi: 10.1097/QAD.0000000000000862. AIDS. 2015. PMID: 26558544 Free PMC article. Clinical Trial.
Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome.
Aboulker JP, Babiker A, Chaix ML, Compagnucci A, Darbyshire J, Debré M, Faye A, Giaquinto C, Gibb DM, Harper L, Saïdi Y, Walker AS; Paediatric European Network for Treatment of AIDS. Aboulker JP, et al. AIDS. 2004 Jan 23;18(2):237-45. doi: 10.1097/00002030-200401230-00013. AIDS. 2004. PMID: 15075541 Clinical Trial.
16 results